BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34953394)

  • 1. Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment.
    Lin TE; Yang CR; Chou CH; Hsu JY; Chao MW; Sung TY; Hsieh JH; Huang WJ; Hsu KC
    Biomed Pharmacother; 2022 Feb; 146():112459. PubMed ID: 34953394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
    Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
    Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of a novel pyrrolo[2,3-b]pyridine as a selective CDK8 inhibitor offers a new approach against psoriasis.
    Yan YY; Wang YM; Shen JH; Jian YJ; Lei CC; Wang Q; Liu C; Zhang XX; Liu XH
    Biomed Pharmacother; 2024 Jun; 175():116705. PubMed ID: 38713949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
    Wang T; Yang Z; Zhang Y; Yan W; Wang F; He L; Zhou Y; Chen L
    Eur J Med Chem; 2017 Mar; 129():275-286. PubMed ID: 28231524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of indolin-2-one derivatives as novel cyclin-dependent protein kinase 8 (CDK8) inhibitors.
    Hsu JY; Hsu KC; Sun C; Chou CH; Lin TE; Sung TY; Tseng HJ; Yen SC; Yang CR; Huang WJ
    Biomed Pharmacother; 2023 Mar; 159():114258. PubMed ID: 36708700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Search of Novel CDK8 Inhibitors by Virtual Screening.
    Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors.
    Martínez-González S; García AB; Albarrán MI; Cebriá A; Amezquita-Alves A; García-Campos FJ; Martínez-Gago J; Martínez-Torrecuadrada J; Muñoz IG; Blanco-Aparicio C; Pastor J
    Eur J Med Chem; 2020 Sep; 201():112443. PubMed ID: 32599324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
    Solum E; Hansen TV; Aesoy R; Herfindal L
    Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel CDK8 inhibitor with poly-substituted pyridine core: Discovery and anti-inflammatory activity evaluation in vivo.
    Chen X; Yan Y; Cheng X; Zhang Z; He C; Wu D; Zhao D; Liu X
    Bioorg Chem; 2023 Apr; 133():106402. PubMed ID: 36791618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease
    Yan Y; Xing C; Xiao Y; Shen X; Zhang Z; He C; Shi JB; Liu M; Liu X
    J Med Chem; 2022 May; 65(10):7334-7362. PubMed ID: 35536548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors.
    Lin TE; Yen D; HuangFu WC; Wu YW; Hsu JY; Yen SC; Sung TY; Hsieh JH; Pan SL; Yang CR; Huang WJ; Hsu KC
    Protein Sci; 2024 Jun; 33(6):e5007. PubMed ID: 38723187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
    Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
    J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Philip S; Kumarasiri M; Teo T; Yu M; Wang S
    J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
    Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
    He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK8/19 Mediator kinases potentiate induction of transcription by NFκB.
    Chen M; Liang J; Ji H; Yang Z; Altilia S; Hu B; Schronce A; McDermott MSJ; Schools GP; Lim CU; Oliver D; Shtutman MS; Lu T; Stark GR; Porter DC; Broude EV; Roninson IB
    Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10208-10213. PubMed ID: 28855340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDK1 in NF-κB signaling is a target of Xanthium strumarium methanolic extract-mediated anti-inflammatory activities.
    Hossen MJ; Cho JY; Kim D
    J Ethnopharmacol; 2016 Aug; 190():251-60. PubMed ID: 27286918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.